Amphastar Pharmaceuticals Inc
NASDAQ:AMPH
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
20.62
40.85
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Net Margin
Amphastar Pharmaceuticals Inc
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| US |
|
Amphastar Pharmaceuticals Inc
NASDAQ:AMPH
|
1.2B USD |
15%
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
1T USD |
31%
|
|
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP |
-4%
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
504B USD |
27%
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
252.4B CHF |
15%
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
210.7B GBP |
16%
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
206.8B CHF |
26%
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
245.9B USD |
30%
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.4T DKK |
33%
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
209B USD |
-126%
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
143B USD |
16%
|
Amphastar Pharmaceuticals Inc
Glance View
Amphastar Pharmaceuticals Inc., established in the heart of Rancho Cucamonga, California, has carved out a significant niche in the pharmaceuticals industry with its diverse portfolio centered on developing, manufacturing, and marketing generic and proprietary injectable and inhalation products. Emerging from its storied beginnings in the mid-1990s, the company’s pragmatic approach to pharmaceutical innovation emphasizes affordability and accessibility. Through strategic acquisitions and a robust in-house research and development team, Amphastar has consistently expanded its product lines, which include critical care, anti-infective, hormonal, and neuromuscular medications, seamlessly marrying clinical necessity with cost efficiency to serve both the domestic U.S. market and an expanding international clientele. Key to Amphastar's business model is its vertically integrated production process, which enables it to exercise stringent control over quality while simultaneously optimizing cost-effectiveness. The company's financial engine is fueled by its generic drug segment, where it capitalizes on the expiration of branded drug patents. By swiftly introducing generic counterparts, Amphastar taps into established demand, thus ensuring steady revenue streams. Additionally, the company's proprietary products, developed through committed R&D efforts, serve to differentiate its offerings in an otherwise commoditized sector, enabling premium pricing and fostering a competitive edge. This clever blend of generic and proprietary product strategy, paired with operational efficiency, underscores Amphastar's role as a formidable player in the pharmaceuticals market, adeptly navigating the complex landscape of regulatory compliance and healthcare trends.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Amphastar Pharmaceuticals Inc's most recent financial statements, the company has Net Margin of 15.4%.